Acute Myeloid Leukemia Coverage From Every Angle
Editor:
Rebecca Olin, MD, MS
Advertisement
Advertisement

Ongoing CE Activities

Acute Leukemia (AML and ALL): From Precision Medicine to Immunotherapy
Acute Leukemias Update, Issue 1, 2020
Acute Myeloid Leukemia: What’s New on the Horizon
Advances in Targeted Therapies in AML and MDS: A Bullseye Approach to FLT3, IDH, and HMAs
AML Expert Guidance on Current Standards and New Directions in Patient Care
Applying Precision Medicine for Patient-Centered, Quality Care for Acute Myeloid Leukemia
ASH 2019 Annual Meeting Highlights in Acute Myeloid Leukemia
Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents
Clinical Management of PNH and AML in an Era of Novel Therapies
Community Practice Connections™: 23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of Novel Therapies in AML
Continuing Education Information for Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
Does Caspofungin Trump Fluconazole for Fungal Infections in Pediatric AML?
Elevated MDS/AML Risk Post-Chemotherapy for 22 of 23 Solid Cancers
Enasidenib May Achieve Remission in IDH2 Mutant Positive AML Patients
Evolving Practice in AML: A Case-based Guide to New and Emerging Treatment Options
Expanding Therapeutic Options in High-Risk AML
Exploring Current Management Paradigms for Acute Myeloid Leukemia in Patients Not Eligible for Intensive Therapy
FLT3 Inhibitors in AML: A Paradigm Shift to Improve Prognosis
Focus on Advancing Treatment for Acute Myeloid Leukemia
Hematology Consults: Moving Toward Precision Medicine in Treating Newly Diagnosed Acute Myeloid Leukemia
Individualizing the Management of Hematologic Malignancies: Genomics, Targeted Therapeutic Options, and Treatment Sequencing
Looking to the Future With Hope: Advances in the Treatment of AML
Medical Crossfire®: Uncovering the Potential Impact of Emerging Data and Ongoing Clinical Trials in AML
Myeloid Malignancy Discoveries
NCCN Pharmacy Updates: New Targets & Treatment Options for AML
New Paradigms in the Treatment of Acute Myeloid Leukemia
New Paradigms in the Treatment Options for ALL and AML: European Perspective
Oncology Briefings: Application of Novel Therapies for the Treatment of Acute Myeloid Leukemia
Online! Medical Crossfire®: Hematologic Malignancies
Pathology Perspectives: Establishing the Role of Predictive Markers and Testing Strategies in AML Management
Practical Strategies for Optimizing IDH Inhibitor-based Therapy in Relapsed/Refractory AML
Proceedings from the First Annual Oncology Nursing Retreat
Reduced-Intensity Treatment Effective in Elders With Acute Myeloid Leukemia
Research Report IDH Inhibitor-based Therapy in AML
Study Confirms Benefit of Treosulfan-Based Conditioning in AML/MDS
Translational Landscape of Cell Therapy for AML: CARs and Beyond – Module 4
Viewpoints in AML: Taking Progress Forward
Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.